PURPOSE: The selective inhibition of tyrosine kinases is a promising strategy in the treatment of several human malignancies. This study aimed to clarify expression patterns of therapeutically addressable receptor tyrosine kinases in colorectal cancer. MATERIALS AND METHODS: In this study, we used tissue arrays to analyze 263 specimen of colorectal carcinoma for the expression of the tyrosine kinases c-kit (CD117), epidermal growth factor receptor (EGF-R), and platelet-derived growth factor receptor (PDGF-R). Staining patterns were then correlated with tumor stage and survival. RESULTS: Five tumors (1.9%) showed a strong expression of c-kit (CD117), while in 40 samples (15.2%), a weak/intermediate expression was observed. Positive staining did not correlate with histopathological parameters although a trend toward a better survival of c-kit-positive patients was observed. No positivity for PDGF-R was observed in 263 samples of colorectal carcinomas. Positive EGF-R expression was identified in 39 cases (15.2%), whereas 218 samples (84.8%) stained negative. CONCLUSIONS: Our study confirms that expression of the tyrosine kinases c-kit and PDGF-R are rare in colorectal carcinomas and do not correlate with tumor stage.
PURPOSE: The selective inhibition of tyrosine kinases is a promising strategy in the treatment of several humanmalignancies. This study aimed to clarify expression patterns of therapeutically addressable receptor tyrosine kinases in colorectal cancer. MATERIALS AND METHODS: In this study, we used tissue arrays to analyze 263 specimen of colorectal carcinoma for the expression of the tyrosine kinases c-kit (CD117), epidermal growth factor receptor (EGF-R), and platelet-derived growth factor receptor (PDGF-R). Staining patterns were then correlated with tumor stage and survival. RESULTS: Five tumors (1.9%) showed a strong expression of c-kit (CD117), while in 40 samples (15.2%), a weak/intermediate expression was observed. Positive staining did not correlate with histopathological parameters although a trend toward a better survival of c-kit-positive patients was observed. No positivity for PDGF-R was observed in 263 samples of colorectal carcinomas. Positive EGF-R expression was identified in 39 cases (15.2%), whereas 218 samples (84.8%) stained negative. CONCLUSIONS: Our study confirms that expression of the tyrosine kinases c-kit and PDGF-R are rare in colorectal carcinomas and do not correlate with tumor stage.
Authors: Christian F Singer; Gernot Hudelist; Wolfgang Lamm; Ruth Mueller; Klaus Czerwenka; Ernst Kubista Journal: Endocr Relat Cancer Date: 2004-12 Impact factor: 5.678
Authors: Rohit Bhargava; Beiyun Chen; David S Klimstra; Leonard B Saltz; Cyrus Hedvat; Laura H Tang; William Gerald; Julie Teruya-Feldstein; Philip B Paty; Jing Qin; Jinru Shia Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Reinhard Kopp; Elisabeth Rothbauer; Maximilian Ruge; Hans Arnholdt; Joachim Spranger; M Muders; Doris G Pfeiffer; Friedrich Wilhelm Schildberg; Andreas Pfeiffer Journal: Recent Results Cancer Res Date: 2003
Authors: Michael Medinger; Manuela Kleinschmidt; Klaus Mross; Barbara Wehmeyer; Clemens Unger; Hans-Eckart Schaefer; Renate Weber; Marc Azemar Journal: Pathol Oncol Res Date: 2010-02-23 Impact factor: 3.201